Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
grade B 12.32 6.67% 0.77
INVA closed up 6.67 percent on Monday, April 6, 2020, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical INVA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Wide Bands Range Expansion 6.67%
Overbought Stochastic Strength 6.67%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.65%
Wide Bands Range Expansion 1.65%
Overbought Stochastic Strength 1.65%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.50%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.
Medicine Drugs Glucocorticoids Organofluorides

Is INVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.35
52 Week Low 7.58
Average Volume 910,466
200-Day Moving Average 12.52
50-Day Moving Average 12.82
20-Day Moving Average 10.75
10-Day Moving Average 11.52
Average True Range 0.96
ADX 27.09
+DI 21.76
-DI 17.85
Chandelier Exit (Long, 3 ATRs ) 10.68
Chandelier Exit (Short, 3 ATRs ) 10.46
Upper Bollinger Band 13.40
Lower Bollinger Band 8.10
Percent B (%b) 0.8
BandWidth 49.26
MACD Line -0.21
MACD Signal Line -0.56
MACD Histogram 0.3492
Fundamentals Value
Market Cap 1.35 Billion
Num Shares 109 Million
EPS 0.80
Price-to-Earnings (P/E) Ratio 15.40
Price-to-Sales 7.61
Price-to-Book 0.00
PEG Ratio 0.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.00
Resistance 3 (R3) 12.94 12.66 12.88
Resistance 2 (R2) 12.66 12.49 12.69 12.84
Resistance 1 (R1) 12.49 12.38 12.58 12.55 12.81
Pivot Point 12.21 12.21 12.25 12.24 12.21
Support 1 (S1) 12.04 12.04 12.13 12.10 11.83
Support 2 (S2) 11.76 11.93 11.79 11.80
Support 3 (S3) 11.59 11.76 11.76
Support 4 (S4) 11.65